Pegipanermin

{
  "id": "MLC-T-ONC-015911",
  "term": "Pegipanermin",
  "field": "Oncology and biomedicine",
  "definition": "A pegylated, human, engineered dominant-negative tumor necrosis factor (TNF; TNF-alpha) variant devoid of TNF receptor-binding activity, with potential anti-inflammatory activity. Upon administration, pegipanermin forms heterotrimers with native soluble TNF (sTNF) but not membrane-bound transmembrane TNF (tmTNF). This prevents the binding of sTNF with TNF receptors and inhibits sTNF pro-inflammatory signaling, thereby reducing inflammation. TNF, a pro-inflammatory cytokine, is upregulated in various diseases and in cytokine storm. sTNF signaling, primarily via TNF receptor 1 (TNFR1; CD120a; p55/p60), may be responsible for exacerbation of existing inflammatory response while tmTNF signaling, primarily via TNF receptor 2 (TNFR2; CD120b; p75/p80), plays an important role in immune system development and cell survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pegipanermin/"
}